Business Context and Reporting Period
This Form 6-K filing by Ascendis Pharma A/S covers the month of August 2026, with the report dated August 12, 2026. The document primarily addresses a corporate action involving equity compensation rather than periodic financial results.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on the grant of employee warrants.
Material Changes
- Warrant Grant: On August 11, 2026, the Board of Directors granted 15,060 warrants to certain employees.
- Exercise Price: The exercise price is set at US $254.57 per share, based on the closing price on the date of grant.
- Vesting Schedule: 25% of the warrants vest on the one-year anniversary of the grant date. The remaining 75% vest monthly at a rate of 1/36th thereafter, subject to continued service.
- Articles of Association: The Company amended its Articles of Association to facilitate this grant.
- Remaining Pool: After this grant, 1,524,443 warrants remain available for future issuance under the Articles of Association.
Guidance, Outlook, and Risks
The filing does not contain financial guidance, management commentary on operational outlook, or specific risk factors beyond the standard vesting conditions tied to continued service and potential exit events.
Investor Verification Checklist
- Verify the total number of outstanding warrants and the remaining pool size (1,524,443) in the updated Articles of Association.
- Confirm the impact of the 15,060 new warrants on potential future dilution.
- Review the specific "exit events" defined in the Articles of Association that could trigger accelerated vesting.
- Check subsequent filings for the next quarterly or annual report to obtain actual financial performance metrics absent from this 6-K.